Read Important Information on Helixate® FS, Antihemophilic Factor (Recombinant)

Read Important Information on Helixate® FS, Antihemophilic Factor (Recombinant)

Twice-weekly Dosing Available to Meet Your Patients' Needs

Zero bleeds (median AsBR*) regardless of dosing regimen

The recommended starting regimen (administered 2x or 3x weekly) is

  • 20-50 IU/kg for patients ≥12 years
  • 30-50 IU/kg for patients <12 years

Adjust regimen based on patient response

  • Patients <12 years may require more frequent or higher doses

Protection delivered with a low number of factor units for both dosing regimens

  • 2x weekly
    • 35 IU/kg for patients of all ages
  • 3x weekly
    • 30 IU/kg for patients ≥12 years
    • 32 IU/kg for patients <12 years

*Annualized spontaneous bleeding rate in clinical trials (IQR=0–2.4 for patients ≥12 years; 0–2.2 for patients <12 years). Median doses used in AFSTYLA clinical trials.

Choose 2x or 3x weekly dosing








Prescription calculator

Other dosing regimens

On-demand treatment

On-demand dosing chart

Perioperative management

Perioperative dosing chart
Dosing formula

The dose to achieve a desired in vivo peak increase in Factor VIII level may be calculated using the following formula:

Dosing Formula

The amount of AFSTYLA to be administered and the frequency of administration should always be oriented to the clinical effectiveness in the individual case.

You are now leaving the current website.

Do you want to continue?

No Yes